The aim of our study has been to analyze the clinical relevance of Gal-1 expression as a prognostic factor using the GLIOCAT cohort, a homogeneously treated and the largest GBM cohort ever studied for this protein. The gene discussed is LGALS1; the disease is glioblastoma.